Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
$1.54
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.54
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.11 - $4.59
Previous CloseN/A
Volume359.61K
Average Volume (3M)3.71M
Market Cap
$407.20M
Enterprise Value$466.18M
Total Cash (Recent Filing)$454.28M
Total Debt (Recent Filing)$64.53M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Oct 30, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding266,141,420
10 Day Avg. Volume2,388,376
30 Day Avg. Volume3,710,395
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue15.57
Enterprise Value/Gross Profit-23.14
Enterprise Value/Ebitda-1.97
Forecast
1Y Price Target
$8.52Price Target Upside453.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAutolus posted a strong 2Q:25 with $21M in Aucatzyl sales, above both analyst and Street expectations.
Market OpportunitiesAutolus plans to file for accelerated approval with the single-arm Phase II data, and subsequently conduct a randomized Phase III trial versus standard of care to support full approval.
Product PerformanceObe-cel is achieving robust B-cell depletion and CAR-T cell expansion, with an intriguing signal of longer persistence than other CAR-T cell therapies in the autoimmune setting.
Bears Say
Market ChallengesAutolus shares are down roughly 10% due to the delay and lack of clarity on timing for a potential EU launch for Aucatzyl.
Regulatory UncertaintyAucatzyl is facing challenges in EU and UK with uncertainty around EU launch timing and potential impact from MFN.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.10 and its highest was $4.59 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $407.20M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Oct 30, 2025 which is tomorrow.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Aug 12, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.231 by $0.051.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.21.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,141,420 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.231. Following the earnings report the stock price went down -12.551%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.52 (453.25% Upside)
$8.52 (453.25% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.83%
12-Months-Change
Fundamentals
Return on Equity
-52.18%
Trailing 12-Months
Asset Growth
-15.54%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics (AUTL) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative T cell therapies for the treatment of cancer. The company operates primarily in the biotechnology sector, specializing in engineered T cell therapies that harness the power of the immune system to target and destroy cancer cells. Autolus is known for its proprietary platform technology, which allows for the creation of differentiated and highly effective therapies designed to improve patient outcomes in hematological malignancies and solid tumors.
AUTL Company Deck
AUTL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong launch and positive reception of Obe-cel in the US, with significant progress in regulatory approvals and treatment center expansion. However, there are ongoing challenges related to high costs, operational losses, and delayed cash receipts, as well as market access difficulties in Europe.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.52
▲(453.25% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
9.87% Mutual Funds
0.19% Other Institutional Investors
89.30% Public Companies and Individual Investors